Clinical Trials Sponsored by Pharm-Olam International

Total 123 results

Persephone Biosciences
Pharm-Olam International

Recruiting

Development and Analysis of a Stool Bank for Cancer Patients

Carcinoma, Non-Small-Cell Lung | Carcinoma, Colorectal

United States
Circassia Limited
Pharm-Olam International

Completed

House Dust Mite Observational Study

Rhinoconjunctivitis

Canada
Seres Therapeutics, Inc.
Pharm-Olam International

Completed

SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence

Clostridium Difficile Infection

United States
Helix BioPharma Corporation
Pharm-Olam International

Completed

A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47

Non-Small Cell Lung Cancer

Poland
Nerre Therapeutics Ltd.
Pharm-Olam International

Active, not recruiting

Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis (IPF-COMFORT)

Cough | Idiopathic Pulmonary Fibrosis

United States, United Kingdom, Netherlands
Circassia Limited
inVentiv Health Clinical; Pharm-Olam International

Completed

Phase III Cat-PAD Study

Rhinoconjunctivitis

United States, Poland, Germany, Belgium, Canada, Russian Federation, Hungary, Slovakia, Czechia
Pharm Olam Pharmaceuticals Ltd.

Unknown

PraevoSkin Emulsion in the Prevention of Radiation Induced Dermatitis

Prevention of Radiation Induced Dermatitis.
Circassia Limited
Adiga Life Sciences, Inc.; Pharm-Olam International

Completed

ToleroMune Grass Exposure Unit Study

Grass Allergy | Rhinoconjunctivitis

Canada
Circassia Limited
Adiga Life Sciences, Inc.; Pharm-Olam International

Completed

ToleroMune Grass Follow on Study

Grass Allergy | Rhinoconjunctivitis
Pharm-Olam, LLC
Biomedical Advanced Research and Development Authority

Terminated

Specimen Collection Study From Coronavirus Disease 2019 (COVID-19) Vaccinated Adults and Adolescents (CoVacSpec)

COVID-19

United States, South Africa, Colombia, Guadeloupe, India, Mexico, Puerto Rico
Ology Bioservices
Pharm-Olam, LLC; Chemical, Biological, Radiological, and Nuclear Medical

Withdrawn

Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19 (COMBAAT) (COMBAAT)

Mild to Moderate COVID-19
Astellas Pharma International B.V.

Terminated

Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL) (NADIR)

Chronic Lymphocytic Leukaemia (CLL) | Indolent Non Hodgkin's Lymphoma (iNHL)

Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, United Arab Emirates
Vifor (International) Inc.

Recruiting

Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of Hyperkalaemia (CARE-HK)

Heart Failure | Hyperkalemia

Spain, United States, Belgium, United Kingdom, Switzerland, Italy, Austria
Vifor (International) Inc.

Active, not recruiting

Cross-sectional Study to Assess Prevalence and Burden of CKD-associated Pruritus in Haemodialysis Patients (ReliefCensus)

Chronic Kidney Disease-associated Pruritus

Germany, Italy, Portugal, Spain, Sweden, Switzerland, United Kingdom
Mayne Pharma International Pty Ltd

Terminated

A Safety, Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis

Lamellar Ichthyosis

United States, Spain, Canada, Germany, France, Australia, Israel, Ukraine, United Kingdom
Vifor (International) Inc.

Withdrawn

Cross-sectional Study to Assess Prevalence and Burden of CKD-associated Pruritus in Hemodialysis Patients (CKD)

Chronic Kidney Disease-associated Pruritus
Mayne Pharma International Pty Ltd

Completed

Bioavailability Study of Lozanoc™ 65 mg Itraconazole Capsules in Patients Requiring Prophylaxis

Neutropenia

Australia
Vifor (International) Inc.

Active, not recruiting

RAYALDEE Non Interventional Study (NIS) on Effectiveness in ND-CKD SHPT Patients (PORTRAY)

Chronic Kidney Disease

Germany
Correvio International Sarl

Completed

Study of Normal Conditions of Use, Dosing, and Safety of Intravenous (IV) Administration of Vernakalant (MK-6621-049)

Atrial Fibrillation

Denmark, Spain, Austria, Finland, Germany, Sweden
Mayne Pharma International Pty Ltd

Completed

Steady-State Comparative Bioavailability Study in Prophylaxis Patients of Lozanoc® 50 mg With Sporanox® 100 mg

Neutropenia

Australia
Mayne Pharma International Pty Ltd

Completed

Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis

Plaque Psoriasis

United States, Poland, Ukraine, Georgia
Vifor (International) Inc.

Completed

Bioavailability Study Comparing 2 Vamifeport Oral Formulations in Fasted Versus Fed State in Healthy Subjects

Healthy

United Kingdom
R-Pharm International, LLC
Quintiles, Inc.; OCT Clinical Trials

Completed

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease (CREDO 2)

Rheumatoid Arthritis

United States, Germany, Korea, Republic of, Bulgaria, Poland, Taiwan, Mexico, Hungary, Czechia, United Kingdom, Lithuania, Argentina, Brazil, Colombia, Estonia, Latvia, Russian Federation, Romania
Ever Neuro Pharma GmbH
SITS International

Terminated

Cerebrolysin REGistry Study in Stroke (CREGS-S)

Ischemic Stroke

Austria
Mayne Pharma International Pty Ltd
GlaxoSmithKline

Completed

Evaluate Safety and Tolerability of Calcipotriene Foam 0.005% in Pediatric Subjects With Mild/Moderate Plaque Psoriasis

Psoriasis

United States
Mayne Pharma International Pty Ltd
GlaxoSmithKline

Completed

Safety, Tolerability, PD & PK of Calcipotriene 0.005% Foam, Under Maximal Use in 12-16 Year Olds With Plaque Psoriasis

Psoriasis

United States
Air Liquide Santé International
Euraxi Pharma

Completed

Study on the Use of Inhaled NO (iNO) (POSITIVE)

Pulmonary Hypertension

France, Belgium
UCB Pharma
International Bureau for Epilepsy

Completed

Adverse Event Scale in Patients With Epilepsy (aEscape) - A European Survey for Physicians With Epilepsy Patients

Epilepsy

Italy, Poland, Germany, Romania, Austria, Czech Republic, Spain
Vifor (International) Inc.
Fortrea

Completed

Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With Sickle Cell Disease (ViSionSerenity)

Sickle Cell Disease

United States, France, Greece, Lebanon, United Kingdom
Breath of Life International Pharma Ltd

Withdrawn

A Study to Evaluate the Safety and Efficacy of BOL-DP-o-08 in Patients With Endometriosis Syndrome.

Endometriosis
Breath of Life International Pharma Ltd

Completed

A Phase I Open Label Study to Assess PK and Safety of Plant Cannabis Extract

Healthy

Israel
Breath of Life International Pharma Ltd

Completed

BOL-DP-o-04 in Patients With Low Back Pain and Sciatica

Low Back Pain | Sciatica

Israel
Breath of Life International Pharma Ltd

Withdrawn

BOL-DP-o-05 as an Add-On Treatment of Subjects With Newly Diagnosed Type 1 Diabetes Mellitus

Type1 Diabetes Mellitus
Breath of Life International Pharma Ltd

Terminated

Phase 2a Study Examining the Safety and Efficacy of BOL-DP-o-04 for Treating Diabetic Neuropathy

Diabetic Neuropathy

Israel
R-Pharm International, LLC
IQVIA Pvt. Ltd; OCT Clinical Trials

Completed

Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis (CREDO 4)

Rheumatoid Arthritis

Korea, Republic of, United States, Germany, Hungary, Bulgaria, Poland, Taiwan, Mexico, Czechia, Argentina, United Kingdom, Belarus, Brazil, Colombia, Estonia, Latvia, Lithuania, Russian Federation
R-Pharm International, LLC
Data Management 365; K-Research, LLC

Completed

Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)

COVID-19

Russian Federation
R-Pharm International, LLC
Quintiles, Inc.; OCT Clinical Trials; Mene Research

Completed

Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease (CREDO 1)

Rheumatoid Arthritis

Belarus, Bulgaria, Russian Federation
R-Pharm International, LLC
Quintiles, Inc.; OCT Clinical Trials; Mene Research

Completed

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease (CREDO 3)

Rheumatoid Arthritis

United States, Korea, Republic of, Germany, Czechia, Mexico, Hungary, Poland, Argentina, Brazil, Colombia, Russian Federation
BDD Pharma Ltd
Drug Delivery International Ltd

Completed

A Study to Investigate Delayed-release Tablets

Pain

United Kingdom
Mayne Pharma International Pty Ltd
bioRASI, LLC

Completed

A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice

Head Lice

United States
Mayne Pharma International Pty Ltd
bioRASI, LLC

Completed

Bio-equivalence Study Comparing Permethrin Cream, 5% With Elimite in Patients With Active Scabies.

Scabies

United States
BDD Pharma Ltd
Drug Delivery International Ltd

Completed

Delayed Release Diclofenac Sodium Formulation vs Voltaren®

Pain

United Kingdom
Monsea Ltd.
Harmonium International Inc.; Pharma Agency

Completed

Prevention of Irinotecan Induced Diarrhea by Probiotics

Colorectal Cancer

Slovakia
Tulane University
Mayne Pharma International Pty Ltd

Terminated

Combination Topical Therapy for Treatment of Scalp Actinic Keratoses

Actinic Keratoses

United States
Astellas Pharma Inc
Basilea Pharmaceutica International Ltd

Completed

Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis

Aspergillosis | Invasive Fungal Infection

Korea, Republic of, Belgium, Australia, United States, Germany, Switzerland, Israel, Canada, Argentina, Chile, Malaysia, Thailand, France, Russian Federation, Hungary, Spain, Brazil, China, India, Egypt, Italy, Turkey, Netherlands, Me... and more
Astellas Pharma Inc
Basilea Pharmaceutica International Ltd

Completed

Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi (VITAL)

Invasive Fungal Infections | Aspergillosis

Korea, Republic of, United States, Belgium, Israel, Mexico, Canada, Brazil, Chile, Argentina, France, Thailand, Egypt, Australia, Germany, India, Lebanon, Poland, Russian Federation, South Africa
Astellas Pharma Inc
Basilea Pharmaceutica International Ltd

Completed

A Study to Assess the Safety and Pharmacokinetics of Isavuconazole in Healthy Chinese Volunteers

Healthy Volunteers | Pharmacokinetics of BAL4815 | Pharmacokinetics of BAL8728

China
Astellas Pharma Inc
Basilea Pharmaceutica International Ltd

Completed

Drug Interaction Study of Isavuconazole and Tacrolimus

Healthy Volunteers | Pharmacokinetics of Isavuconazole | Pharmacokinetics of Tacrolimus

United States
Astellas Pharma Inc
Basilea Pharmaceutica International Ltd

Completed

Drug Interaction Study of Isavuconazole and Cyclosporine

Healthy

United States
R-Pharm International, LLC
IQVIA RDS Ireland Ltd; Thermo Fisher Scientific FS

Completed

Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4

Rheumatoid Arthritis

Bulgaria, Moldova, Republic of

Clinical Trials Sponsored by Pharm-Olam International

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations